Alector Inc is a clinical-stage biopharmaceutical company that is focused on the development of therapies for neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. The company's approach involves developing antibody-based therapies that target the immune system rather than the central nervous system, with the goal of restoring the balance between the two systems and slowing or halting the progression of the disease. Alector's pipeline includes a number of programs in various stages of clinical development, with its lead candidate, AL001, currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. The company is headquartered in South San Francisco, California and was founded in 2013.
Alector Inc is a clinical-stage biopharmaceutical company that is focused on the development of therapies for neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. The company's approach involves developing antibody-based therapies that target the immune system rather than the central nervous system, with the goal of restoring the balance between the two systems and slowing or halting the progression of the disease. Alector's pipeline includes a number of programs in various stages of clinical development, with its lead candidate, AL001, currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. The company is headquartered in South San Francisco, California and was founded in 2013.